Tsu-Yi Chao

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert et al. · Journal of Clinical Oncology · 2011 · 1.6K citations

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 950 citations

Oncology, Phase 2B/3, Afatinib Versus Placebo +9

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

Chiun Hsu, Chao A. Hsiung, Ih‐Jen Su et al. · Hepatology · 2008 · 305 citations · Full text

The Uniform Approach to Breast Fine Needle Aspiration Biopsy

Marluce Bibbo, Andrea Abati, Alex Ferenczy et al. · Acta Cytologica · 1996 · 145 citations

Medical Imaging, Uniform Approach, Cancer Detection +8

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP

Ming–Shen Dai, Tsu-Yi Chao, Woei-Yau Kao et al. · Annals of Hematology · 2004 · 128 citations

Lymphoid Neoplasia, Hepatology, Preemptive Lamivudine +6